Kiora Pharmaceuticals Inc... (KPRX)
Kiora Pharmaceuticals Statistics
Share Statistics
Kiora Pharmaceuticals has 3M shares outstanding. The number of shares has increased by 1.02% in one year.
| Shares Outstanding | 3M |
| Shares Change (YoY) | 1.02% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 1.12% |
| Shares Floating | 2.77M |
| Failed to Deliver (FTD) Shares | 81 |
| FTD / Avg. Volume | 0.35% |
Short Selling Information
The latest short interest is 35.72K, so 1.19% of the outstanding shares have been sold short.
| Short Interest | 35.72K |
| Short % of Shares Out | 1.19% |
| Short % of Float | 1.2% |
| Short Ratio (days to cover) | 3.74 |
Valuation Ratios
The PE ratio is 3.56 and the forward PE ratio is -1.22. Kiora Pharmaceuticals's PEG ratio is -0.03.
| PE Ratio | 3.56 |
| Forward PE | -1.22 |
| PS Ratio | 0.8 |
| Forward PS | 0.4 |
| PB Ratio | 0.5 |
| P/FCF Ratio | 1.49 |
| PEG Ratio | -0.03 |
Enterprise Valuation
Kiora Pharmaceuticals has an Enterprise Value (EV) of 9.04M.
| EV / Sales | 0.56 |
| EV / EBITDA | 1.59 |
| EV / EBIT | 1.06 |
| EV / FCF | 1.06 |
Financial Position
The company has a current ratio of 4.94, with a Debt / Equity ratio of 0.
| Current Ratio | 4.94 |
| Quick Ratio | 4.94 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 210.31 |
Financial Efficiency
Return on Equity is 13.95% and Return on Invested Capital is 9.39%.
| Return on Equity | 13.95% |
| Return on Assets | 9.85% |
| Return on Invested Capital | 9.39% |
| Revenue Per Employee | $1.33M |
| Profits Per Employee | $299.56K |
| Employee Count | 12 |
| Asset Turnover | 0.44 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2.07M |
| Effective Tax Rate | 36.49% |
Stock Price Statistics
The stock price has increased by -31.43% in the last 52 weeks. The beta is -0.53, so Kiora Pharmaceuticals's price volatility has been lower than the market average.
| Beta | -0.53 |
| 52-Week Price Change | -31.43% |
| 50-Day Moving Average | 3.11 |
| 200-Day Moving Average | 3.53 |
| Relative Strength Index (RSI) | 59.33 |
| Average Volume (20 Days) | 23.28K |
Income Statement
In the last 12 months, Kiora Pharmaceuticals had revenue of 16.02M and earned 3.59M in profits. Earnings per share was 0.93.
| Revenue | 16.02M |
| Gross Profit | 16.02M |
| Operating Income | 4.51M |
| Net Income | 3.59M |
| EBITDA | 5.7M |
| EBIT | 5.68M |
| Earnings Per Share (EPS) | 0.93 |
Balance Sheet
The company has 3.79M in cash and 57.17K in debt, giving a net cash position of 3.74M.
| Cash & Cash Equivalents | 3.79M |
| Total Debt | 57.17K |
| Net Cash | 3.74M |
| Retained Earnings | -143.38M |
| Total Assets | 36.48M |
| Working Capital | 23.7M |
Cash Flow
In the last 12 months, operating cash flow was 8.56M and capital expenditures -6.26K, giving a free cash flow of 8.55M.
| Operating Cash Flow | 8.56M |
| Capital Expenditures | -6.26K |
| Free Cash Flow | 8.55M |
| FCF Per Share | 2.21 |
Margins
Gross margin is 100%, with operating and profit margins of 28.15% and 22.44%.
| Gross Margin | 100% |
| Operating Margin | 28.15% |
| Pretax Margin | 35.33% |
| Profit Margin | 22.44% |
| EBITDA Margin | 35.58% |
| EBIT Margin | 28.15% |
| FCF Margin | 53.39% |
Dividends & Yields
KPRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 28.13% |
| FCF Yield | 66.93% |
Analyst Forecast
The average price target for KPRX is $10, which is 220.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 220.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jun 11, 2024. It was a backward split with a ratio of 1:9.
| Last Split Date | Jun 11, 2024 |
| Split Type | backward |
| Split Ratio | 1:9 |
Scores
| Altman Z-Score | -3.25 |
| Piotroski F-Score | 7 |